Evidence map›Paper›PMID 16675414›Full record

SynthesisEnvironmental health perspectives2006

Arsenic exposure and type 2 diabetes: a systematic review of the experimental and epidemiological evidence.

Ana Navas-Acien, Ellen K Silbergeld, Robin A Streeter, Jeanne M Clark, Thomas A Burke, Eliseo Guallar

Open access · diamondAbstract readSystematic Review
In one paragraph

Synthesis in Environmental health perspectives, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 150 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
150citing papers in PubMed, 7 pooled it
9.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

150 citing papers in PubMed, 7 syntheses or guidelines pooled it, 334 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Baseline comorbidities in a skin cancer prevention trial in Bangladesh.European journal of clinical investigation · 2013
    Trial
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

90 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ana Navas-AcienDepartment of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland 21205-2223, USA. anavas@jhsph.edu
Ellen K Silbergeld
Robin A Streeter
Jeanne M Clark
Thomas A Burke
Eliseo Guallar
Johns Hopkins University · US

Funding

Mercury, Arsenic, and Carotid AtherosclerosisR01ES012673 · NIEHS · JOHNS HOPKINS UNIVERSITY · PI GUALLAR, ELISEO · 2004 to 2007
$1.4M
NIEHS NIH HHS 1R01 ES012673-01NIEHS NIH HHS R01 ES012673PHS HHS U50CCU322417
6 · The paper itself

Abstract

Chronic arsenic exposure has been suggested to contribute to diabetes development. We performed a systematic review of the experimental and epidemiologic evidence on the association of arsenic and type 2 diabetes. We identified 19 in vitro studies of arsenic and glucose metabolism. Five studies reported that arsenic interfered with transcription factors involved in insulin-related gene expression: upstream factor 1 in pancreatic beta-cells and peroxisome proliferative-activated receptor gamma in preadipocytes. Other in vitro studies assessed the effect of arsenic on glucose uptake, typically using very high concentrations of arsenite or arsenate. These studies provide limited insight on potential mechanisms. We identified 10 in vivo studies in animals. These studies showed inconsistent effects of arsenic on glucose metabolism. Finally, we identified 19 epidemiologic studies (6 in high-arsenic areas in Taiwan and Bangladesh, 9 in occupational populations, and 4 in other populations). In studies from Taiwan and Bangladesh, the pooled relative risk estimate for diabetes comparing extreme arsenic exposure categories was 2.52 (95% confidence interval, 1.69-3.75), although methodologic problems limit the interpretation of the association. The evidence from occupational studies and from general populations other than Taiwan or Bangladesh was inconsistent. In summary, the current available evidence is inadequate to establish a causal role of arsenic in diabetes. Because arsenic exposure is widespread and diabetes prevalence is reaching epidemic proportions, experimental studies using arsenic concentrations relevant to human exposure and prospective epidemiologic studies measuring arsenic biomarkers and appropriately assessing diabetes should be a research priority.

Indexed as

Evidence-Based MedicineAir PollutantsArsenicBangladeshDiabetes Mellitus, Type 2HumansTaiwanAir PollutantsArsenic

Identifiers

PMID16675414
PMCPMC1459913
OpenAlexW2081530642

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.